Ubiquitin/proteasome Pathway Impairment in Neurodegeneration: Therapeutic Implications

Overview

Journal Apoptosis

Publisher Springer

Date 2010 Feb 5

PMID 20131003

Citations 74

Authors

Qian Huang

Maria E Figueiredo-Pereira

Affiliations

Soon will be listed here.

Abstract

The ubiquitin/proteasome pathway is the major proteolytic quality control system in cells. In this review we discuss the impact of a deregulation of this pathway on neuronal function and its causal relationship to the intracellular deposition of ubiquitin protein conjugates in pathological inclusion bodies in all the major chronic neurodegenerative disorders, such as Alzheimer's, Parkinson's and Huntington's diseases as well as amyotrophic lateral sclerosis. We describe the intricate nature of the ubiquitin/proteasome pathway and discuss the paradox of protein aggregation, i.e. its potential toxic/protective effect in neurodegeneration. The relations between some of the dysfunctional components of the pathway and neurodegeneration are presented. We highlight possible ubiquitin/proteasome pathway-targeting therapeutic approaches, such as activating the proteasome, enhancing ubiquitination and promoting SUMOylation that might be important to slow/treat the progression of neurodegeneration. Finally, a model time line is presented for neurodegeneration starting at the initial injurious events up to protein aggregation and cell death, with potential time points for therapeutic intervention.

Citing Articles

Activation of the 26S Proteasome to Reduce Proteotoxic Stress and Improve the Efficacy of PROTACs.

Sedlacek J ACS Pharmacol Transl Sci. 2025; 8(1):21-35.

PMID: 39816802 PMC: 11729432. DOI: 10.1021/acsptsci.4c00408.

Involvement of Glucosamine 6 Phosphate Isomerase 2 (GNPDA2) Overproduction in β-Amyloid- and Tau P301L-Driven Pathomechanisms.

Lachen-Montes M, Cartas-Cejudo P, Cortes A, Anaya-Cubero E, Peral E, Ausin K Biomolecules. 2024; 14(4).

PMID: 38672412 PMC: 11048700. DOI: 10.3390/biom14040394.

Discovery and Development of Cyclic Peptide Proteasome Stimulators.

Nelson S, Harris T, Muli C, Maresh M, Baker B, Smith C Chembiochem. 2023; 25(3):e202300671.

PMID: 38055197 PMC: 10993313. DOI: 10.1002/cbic.202300671.

TACkling Cancer by Targeting Selective Protein Degradation.

Noblejas-Lopez M, Tebar-Garcia D, Lopez-Rosa R, Alcaraz-Sanabria A, Cristobal-Cueto P, Pinedo-Serrano A Pharmaceutics. 2023; 15(10).

PMID: 37896202 PMC: 10610449. DOI: 10.3390/pharmaceutics15102442.

Bisphenol-A (BPA) Impairs Hippocampal Neurogenesis via Inhibiting Regulation of the Ubiquitin Proteasomal System.

Singh S, Tandon A, Phoolmala , Srivastava T, Singh N, Goyal S Mol Neurobiol. 2023; 60(6):3277-3298.

PMID: 36828952 DOI: 10.1007/s12035-023-03249-3.

References

Diaz-Hernandez M, Hernandez F, Martin-Aparicio E, Gomez-Ramos P, Moran M, Castano J . Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci. 2003; 23(37):11653-61. PMC: 6740941. View

Orr H . Neurodegenerative disease: neuron protection agency. Nature. 2004; 431(7010):747-8. DOI: 10.1038/431747a. View

Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E . The ubiquitin pathway in Parkinson's disease. Nature. 1998; 395(6701):451-2. DOI: 10.1038/26652. View

Schwarz K, Eggers M, Soza A, Koszinowski U, Kloetzel P, Groettrup M . The proteasome regulator PA28alpha/beta can enhance antigen presentation without affecting 20S proteasome subunit composition. Eur J Immunol. 2001; 30(12):3672-9. DOI: 10.1002/1521-4141(200012)30:12<3672::AID-IMMU3672>3.0.CO;2-B. View

Welchman R, Gordon C, Mayer R . Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol. 2005; 6(8):599-609. DOI: 10.1038/nrm1700. View

Chondrogianni N, Gonos E . Overexpression of hUMP1/POMP proteasome accessory protein enhances proteasome-mediated antioxidant defence. Exp Gerontol. 2007; 42(9):899-903. DOI: 10.1016/j.exger.2007.01.012. View

Jung T, Catalgol B, Grune T . The proteasomal system. Mol Aspects Med. 2009; 30(4):191-296. DOI: 10.1016/j.mam.2009.04.001. View

Haas A, Bright P . The immunochemical detection and quantitation of intracellular ubiquitin-protein conjugates. J Biol Chem. 1985; 260(23):12464-73. View

Gal J, Strom A, Kwinter D, Kilty R, Zhang J, Shi P . Sequestosome 1/p62 links familial ALS mutant SOD1 to LC3 via an ubiquitin-independent mechanism. J Neurochem. 2009; 111(4):1062-73. PMC: 2766427. DOI: 10.1111/j.1471-4159.2009.06388.x. View

10.

Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M . Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic.... J Pathol. 1988; 155(1):9-15. DOI: 10.1002/path.1711550105. View

11.

Stanhill A, Haynes C, Zhang Y, Min G, Steele M, Kalinina J . An arsenite-inducible 19S regulatory particle-associated protein adapts proteasomes to proteotoxicity. Mol Cell. 2006; 23(6):875-85. DOI: 10.1016/j.molcel.2006.07.023. View

12.

Saigoh K, Wang Y, Suh J, Yamanishi T, Sakai Y, Kiyosawa H . Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet. 1999; 23(1):47-51. DOI: 10.1038/12647. View

13.

Masino L, Musi V, Menon R, Fusi P, Kelly G, Frenkiel T . Domain architecture of the polyglutamine protein ataxin-3: a globular domain followed by a flexible tail. FEBS Lett. 2003; 549(1-3):21-5. DOI: 10.1016/s0014-5793(03)00748-8. View

14.

Moore D, Dawson V, Dawson T . Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses. Neuromolecular Med. 2003; 4(1-2):95-108. DOI: 10.1385/NMM:4:1-2:95. View

15.

Kim S, Nollen E, Kitagawa K, Bindokas V, Morimoto R . Polyglutamine protein aggregates are dynamic. Nat Cell Biol. 2002; 4(10):826-31. DOI: 10.1038/ncb863. View

16.

Ying Z, Wang H, Fan H, Zhu X, Zhou J, Fei E . Gp78, an ER associated E3, promotes SOD1 and ataxin-3 degradation. Hum Mol Genet. 2009; 18(22):4268-81. DOI: 10.1093/hmg/ddp380. View

17.

Kabuta T, Wada K . Insights into links between familial and sporadic Parkinson's disease: physical relationship between UCH-L1 variants and chaperone-mediated autophagy. Autophagy. 2008; 4(6):827-9. DOI: 10.4161/auto.6560. View

18.

Saudou F, Finkbeiner S, Devys D, Greenberg M . Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998; 95(1):55-66. DOI: 10.1016/s0092-8674(00)81782-1. View

19.

Desplats P, Lee H, Bae E, Patrick C, Rockenstein E, Crews L . Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009; 106(31):13010-5. PMC: 2722313. DOI: 10.1073/pnas.0903691106. View

20.

Kwak M, Wakabayashi N, Greenlaw J, Yamamoto M, Kensler T . Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol Cell Biol. 2003; 23(23):8786-94. PMC: 262680. DOI: 10.1128/MCB.23.23.8786-8794.2003. View